EP4240849A4 - Oligonukleotidzusammensetzungen und verfahren dafür - Google Patents
Oligonukleotidzusammensetzungen und verfahren dafürInfo
- Publication number
- EP4240849A4 EP4240849A4 EP21890258.3A EP21890258A EP4240849A4 EP 4240849 A4 EP4240849 A4 EP 4240849A4 EP 21890258 A EP21890258 A EP 21890258A EP 4240849 A4 EP4240849 A4 EP 4240849A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- oligonucleotide compositions
- oligonucleotide
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063111079P | 2020-11-08 | 2020-11-08 | |
| US202163175036P | 2021-04-14 | 2021-04-14 | |
| US202163188415P | 2021-05-13 | 2021-05-13 | |
| US202163196178P | 2021-06-02 | 2021-06-02 | |
| US202163248520P | 2021-09-26 | 2021-09-26 | |
| PCT/US2021/058495 WO2022099159A1 (en) | 2020-11-08 | 2021-11-08 | Oligonucleotide compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4240849A1 EP4240849A1 (de) | 2023-09-13 |
| EP4240849A4 true EP4240849A4 (de) | 2026-04-01 |
Family
ID=81456778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21890258.3A Pending EP4240849A4 (de) | 2020-11-08 | 2021-11-08 | Oligonukleotidzusammensetzungen und verfahren dafür |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4240849A4 (de) |
| JP (1) | JP2023548584A (de) |
| KR (1) | KR20230118716A (de) |
| AU (1) | AU2021373062A1 (de) |
| CA (1) | CA3197311A1 (de) |
| IL (1) | IL302558A (de) |
| MX (1) | MX2023005326A (de) |
| WO (1) | WO2022099159A1 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| EP3664816A4 (de) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | Oligonukleotidzusammensetzungen und verfahren dafür |
| CA3072110A1 (en) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| WO2022046667A1 (en) * | 2020-08-24 | 2022-03-03 | Wave Life Sciences Ltd. | Cells and non-human animals engineered to express adar1 and uses thereof |
| EP4363574A1 (de) * | 2021-06-29 | 2024-05-08 | Korro Bio, Inc. | Verfahren und zusammensetzungen für adar-vermittelte bearbeitung |
| EP4404942A2 (de) * | 2021-09-26 | 2024-07-31 | Wave Life Sciences Ltd. | Zusammensetzungen zur bearbeitung von mecp2-transkripten und verfahren dafür |
| EP4396354A4 (de) * | 2021-09-26 | 2025-12-03 | Wave Life Sciences Ltd | Oligonukleotidzusammensetzungen und verfahren dafür |
| WO2023069603A1 (en) * | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
| EP4479535A1 (de) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide-oligonukleotide zur nukleinsäureeditierung bei der behandlung von hypercholesterinämie |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| JP2025525564A (ja) * | 2022-07-18 | 2025-08-05 | エフ． ホフマン－ラ ロシュ アーゲー | オリゴヌクレオチドの編集 |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| WO2024114908A1 (en) | 2022-11-30 | 2024-06-06 | Eberhard Karls Universität Tübingen | Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4669750A2 (de) | 2023-02-21 | 2025-12-31 | Vib Vzw | Inhibitoren der synaptogyrin-3-expression |
| WO2024175588A1 (en) | 2023-02-21 | 2024-08-29 | Vib Vzw | Oligonucleotides for modulating synaptogyrin-3 expression |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4689110A1 (de) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense-oligonukleotide zur behandlung von neurologischen erkrankungen |
| EP4688143A1 (de) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense-oligonukleotide zur behandlung von lebererkrankungen |
| WO2024220934A1 (en) | 2023-04-21 | 2024-10-24 | University Of Rochester | Nucleic acid molecules for pseudouridylation |
| CN116444593B (zh) * | 2023-04-28 | 2023-12-26 | 南通大学 | 一种7-脱氮鸟苷亚磷酰胺单体的合成方法 |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025015338A1 (en) * | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| CN121794378A (zh) | 2023-08-15 | 2026-04-03 | 艾尔纳公司 | 用于rna编辑的化学修饰的反义寡核苷酸（aso）及组合物 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| AU2024351975A1 (en) * | 2023-09-28 | 2026-04-16 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| AU2024354150A1 (en) * | 2023-09-28 | 2026-03-12 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2025073902A1 (en) | 2023-10-06 | 2025-04-10 | Eberhard Karls Universität Tübingen | Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing |
| WO2025083268A1 (en) | 2023-10-20 | 2025-04-24 | Airna Corporation | Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) * | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025160090A1 (en) * | 2024-01-22 | 2025-07-31 | Wave Life Sciences Ltd. | Technol. ogies useful for oligonucleotide preparation |
| WO2025172372A1 (en) | 2024-02-12 | 2025-08-21 | Airna Corporation | Conjugate for targeted delivery of an antisense oligonucleotide |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026080897A1 (en) | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004189A1 (en) * | 1998-07-14 | 2000-01-27 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
| WO2001023613A1 (en) * | 1999-09-30 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Human rnase h and oligonucleotide compositions thereof |
| WO2018057946A2 (en) * | 2016-09-23 | 2018-03-29 | Board Of Trustees Of Southern Illinois University | Tuning crispr/cas9 activity with chemically modified nucleotide substitutions |
| WO2020001793A1 (en) * | 2018-06-29 | 2020-01-02 | Eberhard-Karls-Universität Tübingen | Artificial nucleic acids for rna editing |
| WO2020154344A1 (en) * | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014074597A1 (en) * | 2012-11-06 | 2014-05-15 | President And Fellows Of Harvard College | Compositions and methods relating to complex nucleic acid nanostructures |
| CN110352244B (zh) * | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| US11866697B2 (en) * | 2017-05-18 | 2024-01-09 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| US11718638B2 (en) * | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| JP7766589B2 (ja) * | 2019-10-06 | 2025-11-10 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
-
2021
- 2021-11-08 KR KR1020237019215A patent/KR20230118716A/ko active Pending
- 2021-11-08 CA CA3197311A patent/CA3197311A1/en active Pending
- 2021-11-08 JP JP2023527250A patent/JP2023548584A/ja active Pending
- 2021-11-08 WO PCT/US2021/058495 patent/WO2022099159A1/en not_active Ceased
- 2021-11-08 MX MX2023005326A patent/MX2023005326A/es unknown
- 2021-11-08 IL IL302558A patent/IL302558A/en unknown
- 2021-11-08 AU AU2021373062A patent/AU2021373062A1/en active Pending
- 2021-11-08 EP EP21890258.3A patent/EP4240849A4/de active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004189A1 (en) * | 1998-07-14 | 2000-01-27 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
| WO2001023613A1 (en) * | 1999-09-30 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Human rnase h and oligonucleotide compositions thereof |
| WO2018057946A2 (en) * | 2016-09-23 | 2018-03-29 | Board Of Trustees Of Southern Illinois University | Tuning crispr/cas9 activity with chemically modified nucleotide substitutions |
| WO2020001793A1 (en) * | 2018-06-29 | 2020-01-02 | Eberhard-Karls-Universität Tübingen | Artificial nucleic acids for rna editing |
| WO2020154344A1 (en) * | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
Non-Patent Citations (7)
| Title |
|---|
| ANZAHAEE MARYAM YAHYAEE ET AL: "Arabinonucleic Acids: 2'-Stereoisomeric Modulators of siRNA Activity", NUCLEIC ACID THERAPEUTICS, vol. 24, no. 5, 11 September 2014 (2014-09-11), US, pages 336 - 343, XP093060210, ISSN: 2159-3337, Retrieved from the Internet <URL:https://www.liebertpub.com/doi/pdf/10.1089/nat.2014.0496> DOI: 10.1089/nat.2014.0496 * |
| DELEAVEY G. F. ET AL: "Designing chemically modified common general oligonucleotides for targeted gene silencing", CHEM BIOL., vol. 19, no. 8, 23 August 2012 (2012-08-23), pages 937 - 954, XP055905926 * |
| HABIBIAN MARYAM ET AL: "Effect of 2'-5'/3'-5' phosphodiester linkage heterogeneity on RNA interference", NUCLEIC ACIDS RESEARCH, vol. 48, no. 9, 21 May 2020 (2020-05-21), GB, pages 4643 - 4657, XP093134741, ISSN: 0305-1048, Retrieved from the Internet <URL:https://watermark.silverchair.com/gkaa222.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA2UwggNhBgkqhkiG9w0BBwagggNSMIIDTgIBADCCA0cGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMPjlmya_Sg5wroXc0AgEQgIIDGAtyt6-G8374AZjr4A3wDFG15Dqe98ZmkUBqGbtljI3egSWUPRJ0P-qPfIP__lSS7nCSd7WbHoJsFLT4MkQUV6x95y_O> DOI: 10.1093/nar/gkaa222 * |
| PRAKASH ET AL: "RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 16, no. 12, 15 June 2006 (2006-06-15), pages 3238 - 3240, XP005422615, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2006.03.053 * |
| PRAKASH T P ET AL: "RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 16, no. 12, 15 June 2006 (2006-06-15), pages 3238 - 3240, XP027965587, ISSN: 0960-894X, [retrieved on 20060615] * |
| See also references of WO2022099159A1 * |
| SHEN WEN ET AL: "2'-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF", NUCLEIC ACIDS RESEARCH, vol. 43, no. 9, 19 May 2015 (2015-05-19), GB, pages 4569 - 4578, XP055863433, ISSN: 0305-1048, Retrieved from the Internet <URL:https://academic.oup.com/nar/article-pdf/43/9/4569/5153015/gkv298.pdf> DOI: 10.1093/nar/gkv298 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022099159A1 (en) | 2022-05-12 |
| CA3197311A1 (en) | 2022-05-12 |
| AU2021373062A9 (en) | 2024-10-24 |
| IL302558A (en) | 2023-07-01 |
| JP2023548584A (ja) | 2023-11-17 |
| AU2021373062A1 (en) | 2023-06-08 |
| KR20230118716A (ko) | 2023-08-11 |
| MX2023005326A (es) | 2023-07-31 |
| EP4240849A1 (de) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4240849A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
| EP4396354A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
| EP4153604A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
| EP3694530A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
| EP3664815A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
| EP4114360A4 (de) | Zusammensetzungen und verfahren zur gezielten rna-abgabe | |
| EP4153771A4 (de) | Zusammensetzungen und verfahren zur dna-cytosin-carboxymethylierung | |
| EP3891284A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
| EP4422645A4 (de) | Oligonukleotidzusammensetzungen und verfahren zur verwendung davon | |
| EP4217477A4 (de) | Zusammensetzungen und verfahren zur hemmung der genexpression | |
| EP4185569C0 (de) | Verfahren und zusammensetzungen zum targeting von pd-l1 | |
| EP4337202A4 (de) | Verfahren und zusammensetzungen zum targeting von pd-l1 | |
| EP4399309A4 (de) | Serpinamodulierende zusammensetzungen und verfahren | |
| EP4153567A4 (de) | Verfahren und zusammensetzungen zum targeting von pd-l1 | |
| EP3500676A4 (de) | Verfahren und zusammensetzungen für gezielten gentransfer | |
| EP4399306A4 (de) | Pah-modulierende zusammensetzungen und verfahren | |
| EP4408995A4 (de) | Zusammensetzungen und verfahren für nukleinsäuremodifikationen | |
| EP4410067A4 (de) | Werkzeug und verfahren für bestückungsanordnung | |
| EP4419677A4 (de) | Dna-zusammensetzungen und zugehörige verfahren | |
| EP4380576A4 (de) | Zusammensetzungen und verfahren zur gezielten rna-abgabe | |
| EP4304774A4 (de) | Zementzusammensetzungen und verfahren dafür | |
| EP4448512A4 (de) | Verfahren und zusammensetzungen zum targeting von pd-l1 | |
| EP4486901A4 (de) | Zusammensetzungen und verfahren zur genomeditierung | |
| EP4146151A4 (de) | Furan-tensidzusammensetzungen und verfahren | |
| EP4463173A4 (de) | Postbiotische zusammensetzungen und verfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230607 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40100318 Country of ref document: HK |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101AFI20251205BHEP Ipc: C12N 9/22 20060101ALI20251205BHEP Ipc: A61K 31/712 20060101ALI20251205BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20260304 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101AFI20260226BHEP Ipc: C12N 9/22 20060101ALI20260226BHEP Ipc: A61K 31/712 20060101ALI20260226BHEP |